Adjuvant S-1 increases short-term survival in patients with resected biliary tract cancer
1. Patients who received adjuvant S-1 had prolonged overall survival and relapse-free survival compared to those who were managed with ...
1. Patients who received adjuvant S-1 had prolonged overall survival and relapse-free survival compared to those who were managed with ...
Click to read this study in Journal of Clinical Oncology.
Click to read this study in JAMA Network Open.
1. Atezolizumab plus capecitabine + bevacizumab performed marginally better with regards to progression free survival in patients with metastatic colorectal ...
Click to read this study in the Journal of Clinical Oncology.
1. Adjuvant capecitabine resulted in fewer instances of disease recurrence and death compared to standard therapy. 2. Overall and failure-free ...
Click to read the study in the European Journal of Cancer.
Click to read the study in The Lancet Oncology.
1. A phase 3 randomized clinical trial showed that combined therapy using a BRAF inhibitor (encorafenib), EGFR monoclonal antibody (cetuximab) ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.
© 2021 2 Minute Medicine, Inc. - Physician-written medical news.